Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.

@article{Dewdney2011AberrantMO,
  title={Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.},
  author={Summer B. Dewdney and Bobbie J. Rimel and Premal H. Thaker and Dominic M. Thompson and Amy P. Schmidt and Phyllis C. Huettner and David G. Mutch and Feng Gao and Paul J Goodfellow},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2011},
  volume={17 8},
  pages={2120-9}
}
PURPOSE Effective treatments for advanced endometrial cancer are lacking. Novel therapies that target specific pathways hold promise for better treatment outcomes with less toxicity. Mutation activation of the FGFR2/RAS/ERK pathway is important in endometrial tumorigenesis. RPS6KA6 (RSK4) is a putative tumor suppressor gene and is a target of the ERK signaling pathway. We explored the role of RSK4 in endometrial cancer. EXPERIMENTAL DESIGN We showed that RSK4 is expressed in normal… CONTINUE READING